{"product_id":"roche-bcg-matrix","title":"Roche  Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHighlights which units to invest in, hold, or divest\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA clear one-page visualization pinpointing strategic business units for streamlined decision-making. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eRoche  BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the complete Roche BCG Matrix you'll receive. Download the exact, fully formatted document for in-depth analysis and strategic planning, ready for your immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRoche's BCG Matrix maps its diverse portfolio, from blockbusters to potential future leaders. Explore the strategic landscape: Stars, Cash Cows, Dogs, and Question Marks are all at play. This offers a glimpse into Roche's product investment and lifecycle management. Understanding these quadrants is key for effective resource allocation and growth strategy. The full BCG Matrix unlocks deeper insights, helping you assess product performance and strategic options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVabysmo (Ophthalmology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVabysmo, a standout in Roche's portfolio, targets severe eye diseases. It generated CHF 3.9 billion in sales during 2024, driven by global demand. The drug's success stems from its dosing flexibility and effectiveness. It treats conditions like wet age-related macular degeneration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhesgo (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhesgo, a combination therapy for breast cancer, has shown strong performance. It significantly contributes to Roche's pharmaceutical sales, with growing demand in China and the US. In 2023, Phesgo's sales reached CHF 2.1 billion. This success highlights Roche's oncology focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcrevus (Multiple Sclerosis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcrevus, a key drug for multiple sclerosis, is a cash cow for Roche, providing steady revenue. In 2024, Ocrevus sales are projected to be around CHF 6 billion. It is a major growth driver in Roche's pharma segment, showcasing its strong neurology presence. This success underscores Roche's ability to meet MS treatment needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemlibra (Hemophilia A)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHemlibra, a key product for Roche, is a star in its BCG matrix due to its substantial revenue generation. This treatment has revolutionized the management of hemophilia A. The drug’s success highlights Roche's commitment to hematological innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eHemlibra generated CHF 4.1 billion in sales for Roche in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHemlibra's market share in the hemophilia A treatment market continues to be strong.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe drug's ongoing clinical trials and approvals support its sustained growth potential.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Oncology Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche's newer oncology products, such as antibody-drug conjugates (ADCs) and bispecific antibodies, are poised for significant growth. These innovative therapies are essential for maintaining Roche's dominance in oncology. Recent collaborations, including deals with Innovent and MediLink Therapeutics, highlight a strategic push to enhance its ADC pipeline and expand its oncology portfolio. These efforts aim to drive future revenue and market share in the evolving cancer treatment landscape. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e2024: Roche's oncology sales are projected to be around CHF 60 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2024: ADC market is expected to reach $20 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2024: Roche's investments in R\u0026amp;D are approximately CHF 13 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eDeals with Innovent and MediLink Therapeutics are worth hundreds of millions USD.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemlibra's CHF 4.1 Billion Triumph in 2023!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHemlibra, a key product for Roche, is a star. In 2023, Hemlibra's sales were CHF 4.1 billion, showcasing its strong market presence. Its ongoing clinical trials support its sustained growth potential within the hemophilia A treatment market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2023 Sales (CHF Billion)\u003c\/th\u003e\n\u003cth\u003e2024 Sales (Projected)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemlibra\u003c\/td\u003e\n\u003ctd\u003e4.1\u003c\/td\u003e\n\u003ctd\u003eOngoing Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003eOngoing Growth\u003c\/td\u003e\n\u003ctd\u003e6.0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVabysmo\u003c\/td\u003e\n\u003ctd\u003eOngoing Growth\u003c\/td\u003e\n\u003ctd\u003e3.9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRituxan\/MabThera (Blood Cancer, Rheumatoid Arthritis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRituxan\/MabThera, a Roche cash cow, still generates substantial revenue despite biosimilar competition. Sales are decreasing, but its market presence is solid. In 2023, the drug brought in CHF 1.7 billion. Roche's new oncology assets are offsetting this decline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHerceptin (Breast and Gastric Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHerceptin remains a significant revenue generator, even with biosimilar competition. It is a cornerstone treatment for HER2-positive breast and gastric cancer. Roche's breast cancer strategy includes multiple assets to mitigate biosimilar effects. In 2023, Herceptin sales were CHF 1.3 billion, reflecting the ongoing impact of biosimilars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvastin (Various Types of Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvastin, a mature cancer treatment, continues to generate revenue for Roche, despite facing biosimilar rivals. It's still a frequently prescribed option for various cancers. In 2023, Avastin's sales were approximately CHF 1.7 billion, reflecting its ongoing market presence. Roche is strategically investing in newer cancer drugs to offset future revenue impacts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Immunodiagnostic Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche's established immunodiagnostic products, a key part of its Diagnostics Division, consistently generate substantial revenue. Demand for these products, crucial for routine healthcare testing, remains robust. These diagnostic tools are essential in various healthcare settings, ensuring a stable revenue stream. In 2024, the Diagnostics Division reported a sales increase, indicating continued market strength.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eSteady Revenue: Immunodiagnostics provide a reliable income source.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh Demand: Products are essential for ongoing healthcare needs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEssential Role: Used in routine testing across healthcare.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSales Growth: The Diagnostics Division saw sales increases in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Chemistry Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical chemistry tests are a cash cow for Roche, particularly in developed markets. These tests are crucial for everyday medical diagnostics, providing a steady income stream. Investments in infrastructure can boost efficiency and enhance cash flow from these products. Roche's Diagnostics Division saw sales of CHF 17.6 billion in 2023, with a significant portion from established tests. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eStable Revenue: Clinical chemistry tests generate consistent income.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket Focus: Primarily successful in developed markets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestment: Infrastructure boosts efficiency and cash flow.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFinancial Data: Roche Diagnostics sales were CHF 17.6 billion in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash Cows: Roche's Revenue Engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche's cash cows generate consistent revenue. These include established drugs and diagnostics. The company leverages these to fund innovation. This financial stability is crucial.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Category\u003c\/th\u003e\n\u003cth\u003e2023 Sales (CHF billions)\u003c\/th\u003e\n\u003cth\u003eKey Features\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRituxan\/MabThera\u003c\/td\u003e\n\u003ctd\u003e1.7\u003c\/td\u003e\n\u003ctd\u003eMature product, biosimilar competition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHerceptin\u003c\/td\u003e\n\u003ctd\u003e1.3\u003c\/td\u003e\n\u003ctd\u003eHER2-positive cancers, biosimilar impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvastin\u003c\/td\u003e\n\u003ctd\u003e1.7\u003c\/td\u003e\n\u003ctd\u003eVarious cancers, biosimilar rivals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunodiagnostics\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003ctd\u003eEssential healthcare testing, steady sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Chemistry Tests\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003ctd\u003eDeveloped markets, infrastructure investments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSusvimo (Ophthalmology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSusvimo, a retinal implant, faces slow market adoption. Its sales are modest versus other eye treatments. Roche aims for a few thousand implants by 2025. This shows efforts to boost its market standing. 2024 sales data is still emerging.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuxturna (Ophthalmology)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuxturna, Roche's gene therapy for inherited retinal disease, shows modest sales. In 2023, Luxturna generated about CHF 340 million. Market access hurdles and patient identification challenges persist. Roche aims to broaden its use to eligible patients. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder COVID-19 Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales of older COVID-19 products have fallen sharply since the pandemic's peak, notably decreasing in 2024. These items no longer significantly boost Roche's overall earnings. In 2023, COVID-19 product sales were CHF 0.8 billion, a decline from CHF 3.3 billion in 2022. Roche expects minimal impact from COVID-19 from 2025 onward.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Pipeline Projects with Redundancy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche strategically streamlined its early-stage pipeline by cutting redundant projects. This move conserves resources otherwise tied to assets with limited near-term prospects. Roche's focus is now on high-potential projects. In 2024, Roche's R\u0026amp;D spending was approximately CHF 13.6 billion. This shift reflects a focus on maximizing return on investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eReduced early-stage projects to cut costs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on assets with higher potential returns.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eR\u0026amp;D spending in 2024: CHF 13.6 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCertain Discontinued Research Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCertain discontinued research programs represent initiatives abandoned due to strategic shifts or disappointing results. These programs no longer receive funding from Roche. This refocusing allows Roche to concentrate on assets with robust scientific evidence. In 2024, Roche's R\u0026amp;D expenditure reached approximately CHF 14.1 billion, reflecting a commitment to promising areas. The company aims to maximize the impact of its R\u0026amp;D investments. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDiscontinued programs free up resources.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRoche prioritizes high-potential assets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eR\u0026amp;D spending reflects strategic decisions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on assets with strong scientific backing.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDogs: Resource Drain in Slow Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs, in the BCG matrix, represent products with low market share in a slow-growing market. They often require significant investment to improve their position. Roche's COVID-19 products and some discontinued programs fit this category. These areas typically drain resources without generating substantial returns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eFinancial Impact (CHF)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 Products (2023)\u003c\/td\u003e\n\u003ctd\u003eSales Decline\u003c\/td\u003e\n\u003ctd\u003e0.8B, down from 3.3B in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscontinued Programs\u003c\/td\u003e\n\u003ctd\u003eResource reallocation\u003c\/td\u003e\n\u003ctd\u003eReduced future spending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Spending (2024)\u003c\/td\u003e\n\u003ctd\u003eStrategic refocusing\u003c\/td\u003e\n\u003ctd\u003e~14.1B total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRG6058 (TIGIT Antibody)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRG6058, Roche's TIGIT antibody, is in Phase III trials for cancers. Roche has scaled back its TIGIT program, creating doubt. The therapy's future hinges on trial results and market adoption. In 2024, Roche's R\u0026amp;D budget is about CHF 13.5 billion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eItovebi (Breast Cancer)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eItovebi (inavolisib) targets advanced breast cancer, fitting the question mark quadrant of Roche's BCG matrix. Launched recently, it has growth potential, yet faces uncertainty. Early sales projections are positive, but sustainability needs market success and clinical results. 2024 data will clarify its trajectory within the breast cancer market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePiaSky (Paroxysmal Nocturnal Hemoglobinuria (PNH))\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePiaSky (crovalimab), a new treatment for PNH, entered the market recently. Its long-term success is still under evaluation. Roche must closely watch PiaSky's market performance. In 2024, the PNH market was valued at approximately $3.5 billion. Decisions on investment or divestment depend on this data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Digital Diabetes Management Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche's new digital diabetes solutions fit the \"Question Mark\" quadrant of the BCG Matrix. This area represents high-growth markets with uncertain market share. The digital diabetes management market is projected to reach $21.6 billion by 2025, growing at a CAGR of 24.9%. Roche's investment hinges on these solutions gaining traction and improving patient outcomes. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMarket growth: Digital diabetes management market expected to reach $21.6B by 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCAGR: Projected CAGR of 24.9% for the digital diabetes market.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eUncertainty: Adoption rates and market share are currently uncertain.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestment Focus: Success depends on patient outcome improvements and market share gains.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoseida Therapeutics' Cell Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePoseida Therapeutics' cell therapies, acquired by Roche, fit into the \"Question Marks\" quadrant of the BCG matrix. These therapies are in early stages, signaling high potential but also substantial risks. Their success hinges on positive clinical trial results and subsequent regulatory approvals. The investment required is significant, and the path to market is uncertain. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eEarly-stage development indicates high potential for future growth.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eClinical trial outcomes and regulatory approvals are crucial for success.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSignificant investment is needed, with an uncertain path to market.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUncertainty and Potential: Navigating the Pharmaceutical Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Roche's portfolio, like RG6058 and Itovebi, face market uncertainty with high growth potential. PiaSky also falls under this category, needing evaluation of market success. Digital diabetes solutions and Poseida's cell therapies further exemplify this.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMarket Status\u003c\/th\u003e\n\u003cth\u003eKey Challenges\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRG6058 (TIGIT)\u003c\/td\u003e\n\u003ctd\u003ePhase III Trials\u003c\/td\u003e\n\u003ctd\u003eTrial results, market adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eItovebi\u003c\/td\u003e\n\u003ctd\u003eRecently launched\u003c\/td\u003e\n\u003ctd\u003eMarket success, clinical results\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePiaSky\u003c\/td\u003e\n\u003ctd\u003eNew to Market\u003c\/td\u003e\n\u003ctd\u003eMarket performance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Diabetes Solutions\u003c\/td\u003e\n\u003ctd\u003eEarly Stage\u003c\/td\u003e\n\u003ctd\u003eAdoption rates, market share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePoseida Therapeutics\u003c\/td\u003e\n\u003ctd\u003eEarly-stage\u003c\/td\u003e\n\u003ctd\u003eClinical trial results, regulatory approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe Roche BCG Matrix uses financial statements, market reports, and analyst valuations to define its strategic framework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070389039488,"sku":"roche-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/roche-bcg-matrix.png?v=1749422464","url":"https:\/\/swotanalysistemplates.com\/products\/roche-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}